Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2005 Rich Duprey	Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt.
The Motley Fool October 17, 2005 Brian Gorman	Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine.
The Motley Fool September 2, 2005 Rich Duprey	Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty.
The Motley Fool October 14, 2005 Rich Duprey	Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
The Motley Fool March 16, 2006 Rich Duprey	Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
The Motley Fool March 3, 2005 Rich Duprey	Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief.
The Motley Fool May 27, 2005 Rich Duprey	Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm.
Chemistry World February 2006	Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development.
The Motley Fool December 18, 2009 Brian Orelli	Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis.
Pharmaceutical Executive December 1, 2005 Anthony Tao	The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late?
The Motley Fool March 1, 2011 Brian Orelli	Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker.
The Motley Fool May 26, 2005 Brian Gorman	Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off.
The Motley Fool July 28, 2005 Rich Duprey	Chiron's Tragic Quarter The biotech vaccine maker barely breaks even but boasts of its ability to meet full-year expectations.
The Motley Fool March 30, 2006 David Compton	Glaxo's New Flu-Fighting Ammo The FDA certifies the drugmaker's Relenza for defense as well as offense. For investors seeking to give their portfolios a shot in the arm, now might be the time to take a closer look at Glaxo.
The Motley Fool October 6, 2004 Rich Duprey	Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool October 22, 2004 Rich Duprey	Chiron Reports Profit, But So What? The flu vaccine debacle overshadows the company's profits and earnings.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool April 27, 2009 Brian Orelli	A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so.
Health October 2007 Sarah Clachar	Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think.
The Motley Fool July 5, 2006 Rich Duprey	Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle.
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool October 19, 2004 Rich Duprey	Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void.
BusinessWeek October 11, 2004	Bird Flu In Thailand: New Fears The death of a 26-year-old Bangkok woman is raising fears that the deadly avian flu may be "learning" how to spread among people -- a step towards a potentially devastating epidemic.
BusinessWeek October 25, 2004 John Carey	A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked.
BusinessWeek February 9, 2004 Catherine Arnst	What You Need To Know About Avian Flu The current avian flu outbreak in Asia is the fifth since 1997 to infect humans. This has raised a red flag for infectious disease experts, who fear the strain could mutate and spark a devastating flu pandemic.
The Motley Fool June 12, 2009 Brian Orelli	Be Careful What You Wish For Do you have the stomach to profit from swine flu?
BusinessWeek September 19, 2005 Catherine Arnst	A Hot Zone In The Heartland Little could be done to contain a deadly avian flu outbreak. Right now, the U.S. has no national pandemic preparedness plan, either for treating large numbers of patients or for dealing with the resulting economic and social disruptions.
The Motley Fool January 3, 2007 Matthew Crews	Henry Schein Herds Immunity The vaccine distributor hopes a strong 2007 will help revive its earnings. Value investors should put Henry Schein on their watch lists until it presents a greater margin of safety.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
BusinessWeek October 24, 2005 John Carey	New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work?
AskMen.com	1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected.
Chemistry World July 24, 2009 Matt Wilkinson	Pharma's shot in the arm? As swine flu cases continue to erupt around the globe, the latest financial results from pharmaceutical companies Roche and GlaxoSmithKline reveal that sales of their antiviral drugs have soared.
BusinessWeek April 4, 2005 Gene G. Marcial	Schein Gets Over The Flu Henry Schein, the top producer of flu vaccines in the U.S., reported notable fourth-quarter earnings despite the mandated stoppage of vaccine production last year.
The Motley Fool October 29, 2004 Selena Maranjian	Flu Shots for the Elite The flu shot shortage offers some food for thought for investors. Here are some statistics showing the establishment has some problems with the priorities when it comes to the flu.
The Motley Fool February 4, 2010 Brian Orelli	Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last?
BusinessWeek January 31, 2005 Arlene Weintraub	Chiron's Flu Aches May Last Awhile Its vaccine rivals are gaining traction -- and its other businesses are just so-so
The Motley Fool November 30, 2006 Brian Lawler	Happy (Sniffle) Holidays (Cough) It's flu season again, and the market for influenza vaccines is hot. Pharma investors, take note.
AskMen.com Jacob Franek	Swine Flu Update With the fall flu season rapidly approaching, a swine flu update is warranted.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
The Motley Fool December 7, 2004 Brian Gorman	ID Biomedical's Shot in the Arm The company appears well-positioned for the coming years, but it may be best to stay cautious on the company.
The Motley Fool June 14, 2005 Rich Duprey	Chiron's Credit Conundrum Standard & Poor's downgrades the biotech's credit rating on seemingly old news. Why now?
The Motley Fool September 16, 2009 Brian Orelli	Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration.
American Family Physician January 15, 2004	Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc.
The Motley Fool December 10, 2004 Rich Duprey	Regulators Quarantine Chiron The FDA sends a warning letter on the heels of a suspension extension by British authorities. Whether shares of the pharmaceutical ultimately finish up or down, the one-two punch from U.S. and British authorities still points to an ailing company.
The Motley Fool November 30, 2005 Brian Gorman	Is BioCryst For Real? Investors may have been right about BioCryst, but for the wrong reasons. Investors were clearly betting a lot on a drug that is still in early phase testing and had failed in the past.
Popular Mechanics July 31, 2007 John Galvin	Spanish Flu Pandemic: 1918 The influenza pandemic of 1918 killed an estimated 50 million people around the world -- 34 million more than died from the First World War in progress alongside it.
AskMen.com	Drug-Resistant Swine Flu Surfaces Health officials have confirmed a case of swine flu that is resistant to Tamiflu, the leading pharmaceutical weapon against the new virus.